Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of BMS-986165 in lupus nephritis
2018-004142-42Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lupus nephritis (LN) comparing BMS-986165 + mycophenolate mofetil with Placebo + mycophenolate mofetil (2 arms). Primary endpoints: Percentage change from baseline in 24-hour urine protein-to-creatinine ratio (UPCR) at Week 24 and Safety: AEs, vital signs, ECGs, laboratory abnormalities. Started Apr 2019; status: completed.
02
Drugs
deucravacitinib
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on 2018-004142-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004142-42.